Activity Stream
@moatrx
• 2 weeks ago
Posted a new blog:
US HR+/HER2- METASTATIC BREAST CANCER KOL MAPPING
US HR+/HER2- METASTATIC BREAST CANCER KOL MAPPING
A 9,146-patient Flatiron Health study found no survival difference among palbociclib, ribociclib, and abemaciclib, so KOL influence decides prescribing share.
The...



